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INTRODUCTION
The endothelium is a dynamic organ with many prop-
erties that takes part in the regulation of the principal
mechanisms of vascular physiology. Its principal func-
tions include the control of blood-tissue exchange and
permeability, the vascular tonus, and the modulation of
inflammatory or coagulatory mechanisms. Many va-
soactive molecules, produced by the endothelium, are
involved in the control of these functions. The most im-
portant is nitric oxide (NO), a gaseous molecule electri-
cally neutral with an odd number of electrons that gives
the molecule chemically reactive radical properties. Al-
ready known in the twentieth century, NO, sometimes
considered as a dangerous molecule, recently valued as
an important endogenous vasodilator factor. Recently, it
was discovered that it is involved in several physiological
mechanisms of endothelial protection (Tab. I). In 1992,
Science elected it as “molecule of the year”; 6 yrs later
three American researchers (Louis Ignarro, Robert Furch-
gott and Fried Murad) obtained a Nobel Prize for Medi-
cine and Physiology “for their discoveries about NO as
signal in the cardiovascular system”. 
NO is synthesized by endothelial cells from L-argy-
nine and oxygen (Fig. 1). Blood flow and laminar shear
stress induce the activation through phosphorilation of
NO synthase (NOS), that catalyzes the conversion reac-
tion from L-arginine to citrullin and NO, through two co-
factors: calmodulin and pteridin-thetraidrobiopterine
(BH4) (Fig. 2). There are at least three isoforms of con-
stitutive NOS: the endothelial form (eNOS), the neuronal
form (nNOS) and the inducible form (iNOS); eNOS, the
calcium-dependent form of the enzyme, is in many cel-
lular types and it is responsible for NO production in
healthy blood vessels. nNOS is a special type of eNOS,
expressed in the central nervous system. iNOS, a form
induced by immunological stimuli (1), is expressed in
the myocytes, in the macrophages and in the endothe-
lial cells. NOS are formed by two distinct catalytic sub-
units, as terminal C-reductase and terminal N-oxyge-
nase domain. In the presence of sufficient amounts of
BH4, these domains work together and synthesize NO.
Otherwise in case of increased oxidative stress they
cause the production of peroxynitrites. The NO pro-
duced induces guanilate cyclase to the synthesis of
cGMP from cGTP. The last molecule causes cellular hy-
perpolarization due to the activation of the potassium
canals. These reactions cause the inhibition of the en-
trance of calcium and, in this way, the vasodilatation in
the cardiovascular system (Tab. I).
ENDOTHELIAL DYSFUNCTION AND NO
Normal vascular tonus depends on the equilibrium be-
tween the vasoconstrictor and vasodilator molecules re-
leased from the endothelium. In healthy endothelium, the
balance is shifted towards vasodilatation due to NO (Tab.
II). Endothelial dysfunction is synonymous with the insuffi-
ciency of endothelium dependent vasodilatation and re-
sults in the failure of vasoactive, anticoagulant and anti-in-
flammatory effects of healthy endothelium. The most im-
portant mechanism for endothelial dysfunction is the re-
duction in NO availability. The substrate insufficiency such
as the reduction in L-arginine in endothelial cells or any
defect in the transport of L-arginine into the cell, the exis-
tence of NOS inhibitors such as asymmetrical dimethy-
larginine (ADMA) and G-monomethyl-L-arginine (L-NM-
MA), increase in the reactive oxygen molecules, reduction
in the diffusion of NO due to intimal thickening, the muta-
tions in the eNOS gene expression, increase in the catab-
olism of NO, cofactor insufficiency and increase in the
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vasoconstrictor molecules released from the endothelium
are the other mechanisms that must be considered in en-
dothelial dysfunction. Endothelial dysfunction coexists
with many disease states in the cardiovascular system and
is known as the first stage of atherosclerosis, which is
probably the most important disease of the modern age. In
the cardiovascular system, other clinical conditions, which
are related with endothelial dysfunction are hypertension,
are hyperglycemia-insulin resistance, dyslipidemia,
menopause, heart failure, variant angina, cardiac syn-
drome X and hyperhomocysteinemia.
NO oppose the atherogenical stimuli preventing vas-
cular structural modifications; it can inhibit the adhesion
of platelets and monocytes, the migration of the smooth
muscular cells and the endothelial apoptosys. It was
demonstrated that NO, for example, inhibits, through S-
nytrosation, key-enzymes of the apoptotic chart (Cas-
pases 6, 7, 8) (2).
I. Aging
Data obtained in humans and in animal experiments
indicate that aging alters the endothelial dependent va-
sodilatation in the big arteries and in the resistance ves-
sels (3). Moreover, aging is associated with a progres-
sive remodeling of the vascular wall, which includes the
thickening of the tunica intima and of the tunica media
and the increase in its rigidity (4). With advancing old
age, smooth muscular cells migrate progressively from
the tunica media and accumulate in the intima (5). This
fact is associated with a progressive decline in en-
dothelial functionality, which causes a reduced re-
sponse to the vasodilating factors, consequent to the
alteration of the expression and/or the activity of NOS
and with an increased formation of free radicals. Aging
is associated with an alteration in the equilibrium be-
tween vasoconstrictor and vasodilating factors re-
leased by the endothelium, or rather with a progressive
reduction in NO and endothelial derived hyperpolarizing
factor (EDHF) associated with an increase in oxygen
free radicals and prostanoids derived from cycle-oxyge-
nase. In addition, it was recently demonstrated that,
with aging, there is an inferior proliferation and migra-
tion of the endothelial cells from the sites near the ath-
TABLE I - EFFECTS OF ENDOTHELIAL NITRIC OXIDE ON THE
CARDIOVASCULAR SYSTEM
￿ Vasodilation
￿ Inhibition of the growth of the vascular wall and of the prolifera-
tion of the smooth muscular cells
￿ Inhibition of adhesion and platelet aggregation
￿ Inhibition of the adhesion of monocytes to the endothelial cells
￿ Suppression of the expression of adhesion molecules (VCAM)
and chemokines (MCP-1)
￿ Stimulation of platelet cGMP production
￿ Inhibition of endotheline-1 release
TABLE II - CAUSES OF DECREASED ENDOTHELIAL NITRIC OXI-
DE BIO-AVAILABILITY
￿ Decreased availability of L-arginine and NOs cofactors
￿ Increase in the levels of endogenous NOs inhibitors
￿ Alterations of NOs localization on the cellular membrane
￿ NOs interactions with proteins and membrane phospholipids
￿ Increase in oxidative stress with NO degradation
￿ Decrease in NOs synthesis (effect of oxydated-LDL) 
Fig. 2 Fig. 1Nitric oxide and cardiovascular risk factors
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erosclerotic lesion, preventing the preservation of inti-
mal integrity, which is normally favored by a healthy en-
dothelium (6).
II. Hypertension
In the case of hypertension, the release of vasocon-
strictor mediators from the endothelium increases. Hy-
pertension is characterized by an increase in the pro-
duction and activity of angiotensin II; it induces en-
dothelin production by way of the mitogen activated
protein kinase (MAPK) pathway. Hypertension stimu-
lates the production of superoxide anions and reactive
oxygen radicals (7) and increases the consumption of
BH4, and inhibits NO production. In the case of nor-
motension, L-NMA reduces the vasodilatation effect of
acetylcholine, but it is inefficacious in patients with hy-
pertension (8). This discovery indicates a decreased
NO-bioavailability, maybe caused by a reduction in
NOS activity due to L-Arginine deficiency, inhibition by
ADMA or BH4 deficiency. An increase in reactive oxy-
gen radicals that produce with NO peroxynitrates could
also be an important factor. Oxidative stress is respon-
sible for this alteration. Then a compensatory mecha-
nism produces hyperpolarizant factor. When the oxida-
tive mechanism ends, NO bioavailability increases and
the compensatory hyperpolarizant mechanism vanish-
es. The important role of NO in vascular function regula-
tion is explained by the interaction with other vasoac-
tives substances, for example, endothelin-1 (ET-1) (9).
ET-1 acts on specific receptors called ETA and ATB. ETA
receptors are situated on smooth muscular cells and
they cause contraction and cellular growth. ETB recep-
tors are situated either on smooth muscular cells, where
they induce contraction, or on the endothelium, where
they induce dilatation that produces NO. NO reduces
ET-1 synthesis. Decreased NO bioavailability plays an
important role in vascular homeostasis due to its direct
effects and its ability to regulate other important fac-
tors, for example, ET-1.
III. Dyslipidemia
Low-density lipoprotein (LDL) causes the occur-
rence of a situation characterized by an increase in
angiotensin II, surface adhesion molecules and reac-
tive oxygen molecules, which results in a low grade
inflammation. This situation provides a base for en-
dothelial dysfunction. Moreover, the oxygen radicals
react with NO and cause the production of peroxyni-
trite in the existence of oxidized LDL. Peroxynitrite in-
hibits eNOS production and also changes the mission
of eNOS from synthesis of NO to synthesis of oxygen
radicals (10). The increase in LDL and decrease in
high density lipoprotein (HDL) causes the disruption
of the caveola complex, which are the specialized in-
vaginations of the endothelial membrane, containing
eNOS (11). Since the cofactors, essential for NO syn-
thesis, are oxidized due to dyslipidemia, the function
of eNOS is negatively affected. 
IV. Diabetes mellitus
Metabolic abnormalities such as hyperglycemia, in-
crease in free fatty acids and insulin resistance cause
endothelial dysfunction by inhibiting NO synthesis or in-
creasing the catabolism of NO. In healthy humans, in-
sulin increases NOS activity by stimulating phospho-
tidylinositol-3 kinase and Akt kinase. In insulin resistant
patients, the signal transduction by insulin through
phosphotidylinositol-3 kinase pathway is impaired. In-
sulin stimulates NOS less and NO production decreas-
es. However, the signal transduction by insulin through
MAPK remains intact. As a result of this pathway, more
endothelin is produced and inflammation and thrombo-
sis increase (12). The phosphotidylinositol-3 kinase
pathway is also responsible for the insulin-mediated
glucose uptake in the cells. So insulin resistance is ag-
gravated in the case of endothelial dysfunction resulting
in a vicious cycle. It is shown that, after administration
of L-NMMA, which is a NOS inhibitor, both endothelium-
dependent vasodilatation and insulin mediated glucose
uptake are impaired (13). Clinical studies with an-
giotensin-converting enzymes (ACE) inhibitors and
statins demonstrated that these agents did not only re-
duce coronary artery disease and death due to cardio-
vascular events, but also prevented the occurrence of
type II diabetes mellitus (14, 15). These findings suggest
a role for endothelial dysfunction in the pathophysiolo-
gy of insulin resistance. Hyperglycemia increases the
production of the superoxide anion due to mitochondri-
al electron transport (17). Superoxide activates protein
kinase C. The activation of protein kinase C, stimulates
membrane bound NAD(P)H oxidase to produce moreRaddino et al
21
superoxide. The reactivity between superoxide and NO
results in peroxynitrite production, peroxynitrite oxidis-
es the BH4, which is a cofactor for NOS. This situation
causes NOS to produce superoxide instead of NO. Su-
peroxide anion also increases the production of ad-
vanced glycation end products (AGEs) (19). The AGEs
increase superoxide and reactive oxygen radical pro-
duction. Moreover, the oxidative stress caused by hy-
perglycemia inhibits DDAH (20). This increases ADMA
levels. As a result, NO synthesis decreases. The in-
crease in the amount of free fatty acids seen in diabetes
mellitus and insulin resistance, affects the NO balance
in an opposite manner by increasing free oxygen radi-
cals, activating protein kinase C and causing dyslipi-
demia. Another mechanism for endothelial dysfunction
in diabetes mellitus and insulin resistance is the in-
crease in the release of vasoconstrictor prostanoids and
endothelin (21). Even, in healthy humans, the adminis-
tration of insulin resulted in an increase in plasma con-
centrations of endothelin-1 (20, 22).
V. Cigarette smoke
Cigarette smoke is a known risk factor for coronary
pathology. In humans it has been shown that in vivo
nicotine reduces endothelial dependent dilation. Most
qualified hypotheses attribute the endothelial damage to
the large number of oxygen free radicals, present in ciga-
rette smoke: oxidative stress determines compromised
NO production. In chronic smokers  endothelial trouble in
the brachial and coronary arteries and also damage in the
coronary microcirculation has been seen (16).
VI. Obesity
Central obesity, in addition to being an important
component of the metabolic syndrome, is a potent pre-
dictor of coronary disease in humans. Many studies ev-
idenced an independent association between obesity
and endothelial damage. In obese patients, endothelial
trouble is due to two mechanisms: the resistance to in-
sulin and the production of adipokines and pro-inflam-
matory cytokines, which promote oxidative stress and a
reduction in NO concentrations (17). High BMI levels
have been associated with the increased expression of
adhesion molecules such as E-selectin, a precocious
endothelial damage marker.
VII. Hyperhomocysteinemia
Homocysteine is a thiol amino acid that lies at a criti-
cal branch point in methionine metabolism. There are
two main metabolic pathways that involve homocys-
teine. In most tissues, methionine is activated by
adenosine triphosphate (ATP) to form S-adenosylme-
thionine (SAM), which serves as a donor for methyl
transferases, including protein arginine methyl trans-
ferases that produce methylarginines. S-adenosylho-
mocysteine (SAH) is a major product of SAM-dependent
methyl transfer reactions, and which can undergo hy-
drolysis to form homocysteine. Homocysteine can ei-
ther undergo condensation with serine to form cys-
tathionine, or undergo remethylation to form methion-
ine. Condensation of homocysteine to cystathionine is
catalyzed by the vitamin B6-dependent enzyme cys-
tathionine β-synthase (CBS). In vascular tissue, the ma-
jor pathway for homocysteine remethylation is cat-
alyzed by the vitamin B12-dependent enzyme methion-
ine synthase (MS) (18). This reaction utilizes 5-methylte-
trahydrofolate, which is generated by 5,10-methylene
tetrahydrofolate reductase (MTHFR).
Hyperhomocysteinemia is characterized by in-
creased production of reactive oxygen radicals, and
folate deficiency, which leads to reduced bioavailabili-
ty of NO and endothelial dysfunction. Homocysteine
increases the production of pro-inflammatory cy-
tokines and the expression of adhesion molecules and
chemotactic factors. This effect is caused by the stim-
ulation of the activation of transcription factors such
as nuclear factor-κB (NF-κB) and sterol regulatory ele-
ment binding protein (SREBP), and the inhibition of
peroxisome proliferator-activated receptors α and γ
(PPAR-α and γ) (19). Since increased methionine levels
result in increased levels of SAM, hyperhomocysteine-
mia leads to increased synthesis of ADMA (20). Homo-
cysteine also causes the inhibition of DDAH, which is
the enzyme responsible for the catabolism of ADMA
(21), leading to a further increase in plasma ADMA lev-
els. Hyperhomocysteinemia is found to be related with
coronary artery disease (22).
VIII. A new cardiovascular risk factor: ADMA
Asymmetric dimethylarginine (ADMA) is a naturally
occurring component of human blood plasma. It isNitric oxide and cardiovascular risk factors
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formed as a metabolic byproduct of continuous protein
turnover in all cells of the body. More than 10 yrs ago
ADMA was first reported to exert biological effects by
inhibiting NO synthesis. It has been recently demon-
strated that elevated ADMA concentrations are associ-
ated with a higher global cardiovascular risk factor. AD-
MA competitively antagonizes arginine as a substrate of
NOS. Moreover, it increases oxidative stress (possibly
via uncoupling of the electron transport between NOS
and L-arginine) and decreases the production/availabil-
ity of endothelium-derived NO (23). As a result, en-
dothelium-dependent vasodilation could be dependent
on the plasma L-arginine/ADMA ratio. Elevated serum
ADMA concentrations have been observed in patients
with other cardiovascular risk factors such as hypercho-
lesterolemia (24), essential hypertension (25) and dia-
betes (26). Recent studies have demonstrated that ele-
vated ADMA levels represent an independent risk factor
for coronary disease in patients with chronic renal fail-
ure (27), are predictors of acute coronary syndromes in
adults (28) and are associated with higher rates of peri-
procedural complications after percutaneous coronary
intervention (PCI) (29); on the other hand, a reduction in
ADMA levels, months after a PCI procedure, indicates a
decreased risk of recurrent cardiovascular events (30).
A recent study by Zhang et al (31) showed that smoking
increases serum ADMA levels. The metabolism of AD-
MA seems to be altered by tobacco smoke; this fact
could represent an additional link between smoking and
endothelial dysfunction (32).
HEART FAILURE AND NITRIC OXIDE
Physiological doses of NO results in positive inotrop-
ic, positive chronotropic and positive lusitropic effects
in the myocardium. In addition, NO paradoxically re-
duces the oxygen requirement of the heart by inhibiting
the mitochondrial metabolism (33). Cardiac NO release
is cyclic, and increases in the early diastolic filling peri-
od. When the preload increases, NO release increases
too. NO is also effective in the Frank-Starling mecha-
nism (34). Moreover, in low doses, NO increases the β-
adrenergic activity in the myocardium. In heart failure,
both iNOS and nNOS increases. In idiopathic dilated
cardiomyopathy it is shown that 80% of NOS activity in
the myocardium is dependent on nNOS (35). The in-
creases in iNOS and nNOS are positively correlated with
the increase in oxidative stress in patients with heart
failure, and moreover, NO produced by iNOS can result
in peroxynitrite production and contractile dysfunction.
The high doses of NO released in heart failure results in
a negative inotropic and negative chronotropic effect
and a reduction in β-adrenergic stimulation (36). Saito et
al (37) reported that the administration of selective iNOS
inhibitors resulted in a significant reduction in mortality,
infarct size and cardiomyocyte hypertrophy in patients
with post-infarction heart failure. In patients with dilated
cardiomyopathy, it is also shown that the contractile ef-
fect of dobutamine is increased with NMMA administra-
tion. In cases that developed resistant cardiogenic
shock, despite intra-aortic balloon pumping and PCI af-
ter myocardial infarction; the administration of L-NMMA
significantly reduced the mortality rate (38). These find-
ings suggest that NO could play a major role in the
pathogenesis of heart failure and the inhibition of this
NO with deleterious effects could be helpful in treat-
ment.
TREATMENT OF ENDOTHELIAL DYSFUNCTION
Due to its role in the pathophysiology and etiology of
several life-threatening diseases such as heart disease,
hypertension, atherosclerosis, dyslipidemia and dia-
betes, endothelial dysfunction is becoming an impor-
tant target in therapeutic approaches. Several treat-
ments have been found to be effective in improving en-
dothelial function.
Aerobic physical exercise has been shown to prevent
the aging related to the reduction in endothelial-mediat-
ed vasodilation (39). A study investigating patients with
coronary heart disease demonstrated that after 4 weeks
of aerobic training there was an improvement in en-
dothelial function measured with a reduction in acetyl-
choline-induced vasoconstriction. The authors pro-
posed that stimulation by shear stress induced by exer-
cise could improve eNOS activity both by promoting its
phosphorylation and by inducing its synthesis in en-
dothelial cells. 
Polyunsaturated  ω-3 fatty acids (40) have been
shown to preserve endothelial function and increase NO
bioavailability; moreover, some authors have suggested
a direct beneficial effect of this molecule on the vascu-Raddino et al
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lar wall through a decrease in the expression of pro-in-
flammatory mediators that could contribute to altering
the physiological vasodilatory mechanisms. 
Dietary supplementation with L-arginine (a substrate
of NOS) seems able to rebalance NO production on the
dysfunctional endothelium, stimulating NOS activity
both directly and indirectly: antagonizing the effects of
ADMA and reducing endothelin-1 synthesis (41). Lerman
et al (42) found a significant improvement in endothelial
function in patients with coronary artery disease after 6
months of L-arginine supplementation. Treated patients
showed a better vasodilatory response after acetyl-
choline induced contraction and reduced endothelin-1
plasmatic levels. In addition, L-arginine supplementation
reduced symptoms in both patients with stable angina
and heart failure. 
Antioxidant vitamins are often thought to be benefi-
cial in the treatment of endothelial dysfunction; howev-
er, the results of clinical studies are not clear. The re-
sults of a few clinical studies show that the benefit of
antioxidant vitamins was positive. The CHAOS study,
which is a secondary prevention study, suggested a
47% decrease in non-fatal myocardial infarction inci-
dence, but no effect on mortality with α-tocopherol. The
SPACE trial, which included end-stage renal failure pa-
tients, showed antioxidant vitamin A treated endothelial
dysfunction (40). But most studies do not support these
results. The possible explanations for disapproving the
results of these studies includes the choice of incorrect
vitamin form (α-tocopherol), insufficient dose, com-
bined treatment with β-carotene, improper choice of
study population and short treatment period. However,
Kinlay et al showed that, long-term, high-dose com-
bined vitamin C and vitamin E treatment failed to im-
prove endothelial function and did not decrease LDL
oxidation (43).
Folic acid may represent a useful therapeutic strate-
gy in endothelial dysfunction. Folic acid administration
is able to reduce serum homocysteine concentration, to
inhibit NOS uncoupling and has itself a direct antioxi-
dant effect. Wilmink et al (44) showed that folic acid in-
hibited postprandial lipid-induced endothelial dysfunc-
tion and caused an increase in urinary excretion of oxy-
gen radicals in healthy volunteers.
An important class of drugs with therapeutic effects
on endothelial dysfunction is the ACE-inhibitor. It has
been shown that ACE-inhibitors inhibit NADPH oxidase
through both bradykinine accumulation and direct ef-
fects. NADPH oxidase inhibition leads to a drop in
oxygen free radical production. In the BANFF study,
quinapril was shown to treat endothelial function in 80
patients with coronary artery disease after 8 weeks of
treatment. It has been found that the effect of ACE in-
hibitors on endothelial function is related to genotype.
Quinapril is found to be ineffective on endothelial
functions in patients with ACE DD genotype. Ghiadoni
et al (45) investigated the effect of different antihyper-
tensive medications on FMD in 168 hypertensive pa-
tients and only perindopril was found to increase
FMD. The HOPE and EUROPE studies showed a re-
duction in clinical cardiovascular end-points with
ramipril and perindopril (46).
Statins have been found to be effective in endothelial
dysfunction both in primary and secondary prevention
studies. These benefits seem to be independent of their
lipid lowering effects (39) and appear to be linked to
their so-called “pleiotropic effects” on the endothelium.
Statins inhibit the activity of plasminogen activator in-
hibitor-1, tissue factor, growth factor and matrix metal-
loproteinases; terminate smooth muscle cell prolifera-
tion and migration and reduce NO levels, reduce apop-
tosis and inflammation and increase angiogenesis.
Estrogen is another agent thought to be effective on
endothelial function preservation. Estrogen increases
NO production and NO dependent vasodilation. It in-
hibits smooth muscle cell proliferation and LDL oxida-
tion. However, despite this evidence, the results of clin-
ical studies like HERS and WHI have suggested an in-
crease in major cardiovascular events with estrogen
treatment (47).
Old generation β-blockers are found not useful in the
treatment of endothelial dysfunction. However, nebivolol
has recently shown a beneficial effect on the endotheli-
um. In addition to its  β1 selective antagonist effect, it ex-
erts a direct vasodilation through NO production. Recent
experimental evidence suggests that the lipophilic prop-
erties of nebivolol could enhance the mechano-sensitive
reactivity of the endothelium to shear stress stimulation.
This mechanical stress induces eNOS activation through
a kinase-dependent mechanism determining calcium ion
release.
In a double-blind randomized study on patients with
essential hypertension, Tzemos et al (48) demonstrated
the efficacy of 8-month treatment with nebivolol (5 mgNitric oxide and cardiovascular risk factors
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per day) and a diuretic (bendrofluazide, 2.5 mg) in im-
proving endothelial function. Nebivolol/bendrofluazide
increased both stimulated and basal endothelial NO re-
lease, whereas for the same degree of blood pressure
(BP) control, atenolol/bendrofluazide had no effect on
NO bioactivity. Therefore, nebivolol could offer addi-
tional vascular protection in treating hypertension.
CONCLUSIONS
As previously explained, endothelial dysfunction re-
sults in an impaired NO production, which results in de-
creased vasodilation and a prothrombotic state. Its
presence is associated with most cardiovascular risk
factors such as hypertension, smoking, hypercholes-
terolemia, homocystinuria and diabetes mellitus. One
common denominator shared by these diseases is the
reduced levels of eNOS in the endothelium. An impaired
endothelial function is known to be the first step to ath-
erosclerosis. Several studies have demonstrated that
the decrease in vasodilatory capacity NO-mediated of
the endothelium (endothelium dependent) is a strong
predictor of future cardiovascular events. This major
risk seems to be independently associated with im-
paired endothelial function: young healthy adults with
impaired endothelial function are more inclined to de-
velop atherosclerosis than adults with preserved en-
dothelium (49). It has been largely demonstrated that
NO represents the most important biological mediator
involved in the regulation of endothelial homeostasis. A
decrease in bioavailability of this molecule appears to
be the final pathway for all cardiovascular risk factors.
In a damaged or altered endothelium several factors
such as oxidative stress, intima thickness and enzymat-
ic inhibition lead to NO depletion, shifting the vascular
balance towards vasoconstriction, inflammation and
thrombosis. Most cardiovascular risk factors act in re-
ducing NO bioavailability through many ways, and this
could be the main final mechanism that links risk factors
to vascular disease and increased odds of cardiovascu-
lar events. According to this hypothesis we should con-
sider endothelial dysfunction as an important target of
new therapeutic strategies. Moreover, impaired NO
availability could be not only the final pathway of all car-
diovascular risk factors but also itself be the cause of
some of them. For example, impairment in NO bioactiv-
ity or endothelial dysfunction involving resistant arteries
may increase the systemic BP in susceptible individu-
als; therefore, giving rise to hypertension. It has been al-
so suggested that insufficient NO production could
have a role in the development of insulin resistance. In
this way, endothelial dysfunction could represent an im-
portant player in the vicious circle of metabolic syn-
drome development.
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